Simulations Plus Inc. Invests $1 Million in Nurocor to Boost Innovations in Biopharma Clinical Development

Reuters

2025/07/15

<a href="https://laohu8.com/S/SLP">Simulations Plus</a> Inc. Invests $1 Million in Nurocor to Boost Innovations in Biopharma Clinical Development

Simulations Plus Inc., a leading provider in the biopharma industry, has announced a $1 million equity investment in Nurocor, a technology company specializing in clinical development. The investment is part of Simulations Plus' Corporate Development Initiative, launched in 2024 to support early-stage tech companies and foster growth within the pharmaceutical sector. Nurocor, founded in 2017, offers a cloud-based software platform that enhances efficiency and automation in clinical trials, ultimately reducing development costs. This strategic investment aims to accelerate innovations in biopharma development, aligning with Simulations Plus' strategy to expand its market reach and deliver faster, cost-effective solutions to its clients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250714193406) on July 14, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2551354461"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551354461\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551354461?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 04:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551354461","market":"nz","top_or_hot":-1,"title":"Simulations Plus Inc. Invests $1 Million in Nurocor to Boost Innovations in Biopharma Clinical Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLP\">Simulations Plus</a> Inc. Invests $1 Million in Nurocor to Boost Innovations in Biopharma Clinical Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Simulations Plus Inc., a leading provider in the biopharma industry, has announced a $1 million equity investment in Nurocor, a technology company specializing in clinical development. The investment is part of Simulations Plus' Corporate Development Initiative, launched in 2024 to support early-stage tech companies and foster growth within the pharmaceutical sector. Nurocor, founded in 2017, offers a cloud-based software platform that enhances efficiency and automation in clinical trials, ultimately reducing development costs. This strategic investment aims to accelerate innovations in biopharma development, aligning with Simulations Plus' strategy to expand its market reach and deliver faster, cost-effective solutions to its clients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250714193406) on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simulations Plus Inc. Invests $1 Million in Nurocor to Boost Innovations in Biopharma Clinical Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimulations Plus Inc. Invests $1 Million in Nurocor to Boost Innovations in Biopharma Clinical Development\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-15 04:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLP\">Simulations Plus</a> Inc. Invests $1 Million in Nurocor to Boost Innovations in Biopharma Clinical Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Simulations Plus Inc., a leading provider in the biopharma industry, has announced a $1 million equity investment in Nurocor, a technology company specializing in clinical development. The investment is part of Simulations Plus' Corporate Development Initiative, launched in 2024 to support early-stage tech companies and foster growth within the pharmaceutical sector. Nurocor, founded in 2017, offers a cloud-based software platform that enhances efficiency and automation in clinical trials, ultimately reducing development costs. This strategic investment aims to accelerate innovations in biopharma development, aligning with Simulations Plus' strategy to expand its market reach and deliver faster, cost-effective solutions to its clients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250714193406) on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLP","symbol_name":"Simulations Plus","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDLbl7bwT:1","article_id":"2551354461","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551354461","pubTimestamp":1752524176,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Simulations Plus Inc., a leading provider in the biopharma industry, has announced a $1 million equity investment in Nurocor, a technology company specializing in clinical development. The investment is part of Simulations Plus' Corporate Development Initiative, launched in 2024 to support early-stage tech companies and foster growth within the pharmaceutical sector. Nurocor, founded in 2017, offers a cloud-based software platform that enhances efficiency and automation in clinical trials, ultimately reducing development costs. This strategic investment aims to accelerate innovations in biopharma development, aligning with Simulations Plus' strategy to expand its market reach and deliver faster, cost-effective solutions to its clients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLP":"Simulations Plus","BK4167":"医疗保健技术"},"translate_title":"Simulations Plus Inc.向Nurocor投资100万美元，以推动生物制药临床开发创新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLP":0.9},"content_text":"Simulations Plus Inc. Invests $1 Million in Nurocor to Boost Innovations in Biopharma Clinical Development\n    \n\n        Simulations Plus Inc., a leading provider in the biopharma industry, has announced a $1 million equity investment in Nurocor, a technology company specializing in clinical development. The investment is part of Simulations Plus' Corporate Development Initiative, launched in 2024 to support early-stage tech companies and foster growth within the pharmaceutical sector. Nurocor, founded in 2017, offers a cloud-based software platform that enhances efficiency and automation in clinical trials, ultimately reducing development costs. This strategic investment aims to accelerate innovations in biopharma development, aligning with Simulations Plus' strategy to expand its market reach and deliver faster, cost-effective solutions to its clients.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250714193406) on July 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}